We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-2.68%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$17.3B
AUM Growth
-$1.1B
Cap. Flow
-$283M
Cap. Flow %
-1.64%
Top 10 Hldgs %
87.61%
Holding
112
New
6
Increased
21
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$42.9M
2
ROIV icon
Roivant Sciences
ROIV
+$41.6M
3
ABCL icon
AbCellera Biologics
ABCL
+$40.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$20.6M
5
IMGN
Immunogen Inc
IMGN
+$17.9M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$469M
2
KYNB
Kyntra Bio
KYNB
+$39.7M
3
BPMC
Blueprint Medicines
BPMC
+$15M
4
KRYS icon
Krystal Biotech
KRYS
+$13.6M
5
VSTM icon
Verastem
VSTM
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.2%
2 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HOOK
76
DELISTED
HOOKIPA Pharma
HOOK
$3.89M 0.02%
442,554
+95,000
+27% +$1.05M
EWTX icon
77
Edgewise Therapeutics
EWTX
$4.8B
$3.88M 0.02%
500,000
– –
GRCL
78
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$3.81M 0.02%
+1,000,000
New +$2.8M
CYPH
79
Cypherpunk Technologies Inc
CYPH
$153M
$3.67M 0.02%
1,172,175
+429,618
+58% +$2.16M
TLIS
80
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$3.66M 0.02%
508,322
– –
IPSC icon
81
Century Therapeutics
IPSC
$375M
$3.63M 0.02%
1,149,340
– –
MRSN
82
DELISTED
Mersana Therapeutics
MRSN
$3.57M 0.02%
43,445
-32,000
-42% -$4.68M
BCEL
83
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$3.46M 0.02%
3,532,760
– –
NGNE icon
84
Neurogene
NGNE
$773M
$3.17M 0.02%
191,087
– –
DSGN icon
85
Design Therapeutics
DSGN
$938M
$3.15M 0.02%
500,000
-126,884
-20% -$776K
XNCR icon
86
Xencor
XNCR
$2.07B
$3.07M 0.02%
123,127
– –
TIL icon
87
Instil Bio
TIL
$51.4M
$2.91M 0.02%
263,689
– –
TNGX icon
88
Tango Therapeutics
TNGX
$4.03B
$2.49M 0.01%
750,000
– –
PCVX icon
89
Vaxcyte
PCVX
$9.32B
$2.44M 0.01%
48,885
– –
ACHL
90
DELISTED
Achilles Therapeutics
ACHL
$2.42M 0.01%
2,557,149
-34,217
-1% -$32.5K
VERA icon
91
Vera Therapeutics
VERA
$2.33B
$2.35M 0.01%
146,464
-186,869
-56% -$1.69M
PRAX icon
92
Praxis Precision Medicines
PRAX
$10.5B
$2.16M 0.01%
125,328
– –
ALGS icon
93
Aligos Therapeutics
ALGS
$41.7M
$2.02M 0.01%
83,056
– –
PMVP icon
94
PMV Pharmaceuticals
PMVP
$71.1M
$2.02M 0.01%
322,024
– –
ITOS
95
DELISTED
iTeos Therapeutics
ITOS
$1.99M 0.01%
150,346
– –
VOR icon
96
Vor Biopharma
VOR
$1.38B
$1.96M 0.01%
31,692
– –
KALA icon
97
KALA BIO
KALA
$15.9M
$1.7M 0.01%
2,324
+788
+51% +$612K
CATX icon
98
Perspective Therapeutics
CATX
$377M
$1.55M 0.01%
+231,929
New +$1.41M
SYRE icon
99
Spyre Therapeutics
SYRE
$9.39B
$1.54M 0.01%
136,404
– –
KYNB
100
Kyntra Bio
KYNB
$30.4M
$643K ﹤0.01%
9,523
-95,972
-91% -$39.7M
1 2 3
4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2023 Portfolio in Review

As of Q2 2023, Julian Baker held 112 positions worth $17.3B, down 6% from $18.4B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Julian Baker's Q2 2023 filing shows 6 new, 21 increased, 12 reduced and 5 closed positions. Its largest new stake was Immunogen Inc: 1,520,097 shares worth $28.7M. The largest sale was Seagen Inc. Common Stock, an estimated $469M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q2 2023 buy was Immunogen Inc: 1,520,097 shares worth $28.7M.
  • Julian Baker added most to Kymera Therapeutics in Q2 2023, an estimated $42.9M increase.
  • Julian Baker's biggest Q2 2023 reduction was Seagen Inc. Common Stock, cutting an estimated $469M.
  • Julian Baker fully exited Blueprint Medicines in Q2 2023, selling an estimated $15M.
  • Julian Baker's ten largest holdings make up 88% of its $17.3B portfolio in Q2 2023.
  • Julian Baker opened 6 new positions and closed 5 in Q2 2023.
  • Julian Baker's portfolio value fell 6% quarter-over-quarter to $17.3B.

Based on Baker Bros. Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.